Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DYAI OTCMKTS:INBP NASDAQ:MURA NASDAQ:RENB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDYAIDyadic International$0.99+2.6%$0.95$0.71▼$2.20$34.94M0.94115,643 shs177,697 shsINBPIntegrated BioPharma$0.29-1.4%$0.29$0.20▼$0.42$9M0.866,468 shs13,900 shsMURAMural Oncology$2.07$2.12$0.95▼$4.74$35.86M2.99456,841 shs267,128 shsRENBRenovaro$0.18-4.0%$0.26$0.17▼$2.10$32.82M0.54876,451 shs2.78 million shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDYAIDyadic International-0.14%+0.04%+29.03%+4.95%-22.14%INBPIntegrated BioPharma+0.94%+7.67%+9.16%-10.55%+26.45%MURAMural Oncology-0.48%0.00%+17.61%-15.16%-37.08%RENBRenovaro-4.03%+1.38%-20.24%-46.95%-70.89%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDYAIDyadic International$0.99+2.6%$0.95$0.71▼$2.20$34.94M0.94115,643 shs177,697 shsINBPIntegrated BioPharma$0.29-1.4%$0.29$0.20▼$0.42$9M0.866,468 shs13,900 shsMURAMural Oncology$2.07$2.12$0.95▼$4.74$35.86M2.99456,841 shs267,128 shsRENBRenovaro$0.18-4.0%$0.26$0.17▼$2.10$32.82M0.54876,451 shs2.78 million shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDYAIDyadic International-0.14%+0.04%+29.03%+4.95%-22.14%INBPIntegrated BioPharma+0.94%+7.67%+9.16%-10.55%+26.45%MURAMural Oncology-0.48%0.00%+17.61%-15.16%-37.08%RENBRenovaro-4.03%+1.38%-20.24%-46.95%-70.89%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDYAIDyadic International 3.00Buy$6.00505.57% UpsideINBPIntegrated BioPharma 0.00N/AN/AN/AMURAMural Oncology 2.50Moderate Buy$12.00479.71% UpsideRENBRenovaro 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest INBP, MURA, DYAI, and RENB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/8/2025DYAIDyadic InternationalCraig HallumSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy(Data available from 9/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDYAIDyadic International$3.49M10.27N/AN/A$0.08 per share12.39INBPIntegrated BioPharma$50.32M0.18$0.04 per share6.50$0.64 per share0.45MURAMural OncologyN/AN/AN/AN/A$8.22 per shareN/ARENBRenovaroN/AN/AN/AN/A$0.89 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDYAIDyadic International-$5.81M-$0.19N/AN/AN/A-134.84%-355.39%-60.66%11/11/2025 (Estimated)INBPIntegrated BioPharma$110K$0.047.17∞N/A2.37%6.36%4.84%9/18/2025 (Estimated)MURAMural Oncology-$128.51M-$8.59N/AN/AN/AN/A-107.76%-87.57%11/12/2025 (Estimated)RENBRenovaro-$88.43M-$0.77N/A∞N/AN/A-60.38%-47.04%9/29/2025 (Estimated)Latest INBP, MURA, DYAI, and RENB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025DYAIDyadic International-$0.06-$0.06N/A-$0.06$0.60 million$0.97 million8/4/2025Q2 2025MURAMural Oncology-$1.13-$1.77-$0.64-$2.78N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDYAIDyadic InternationalN/AN/AN/AN/AN/AINBPIntegrated BioPharmaN/AN/AN/AN/AN/AMURAMural OncologyN/AN/AN/AN/AN/ARENBRenovaroN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDYAIDyadic International5.402.022.02INBPIntegrated BioPharmaN/A3.721.70MURAMural OncologyN/A2.872.87RENBRenovaroN/A0.130.13Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDYAIDyadic International27.95%INBPIntegrated BioPharma25.25%MURAMural Oncology80.21%RENBRenovaro71.41%Insider OwnershipCompanyInsider OwnershipDYAIDyadic International29.50%INBPIntegrated BioPharma67.20%MURAMural Oncology2.20%RENBRenovaro0.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDYAIDyadic International736.19 million25.51 millionOptionableINBPIntegrated BioPharma15030.98 million10.16 millionNot OptionableMURAMural Oncology11917.32 million16.94 millionOptionableRENBRenovaro20172.12 million171.26 millionOptionableINBP, MURA, DYAI, and RENB HeadlinesRecent News About These CompaniesLunai Bioworks subsidiary BioSymetrics and Brigham and Women's Hospital Awarded NIH STTR Grant to Develop AI-Powered Platform for Alcohol Use Disorder TherapeuticsSeptember 11, 2025 | accessnewswire.comARenovaro Inc.: Renovaro Strengthens Balance Sheet Through Debt Conversion and Advances AI-Driven InitiativesSeptember 9, 2025 | finanznachrichten.deLunai Bioworks Inc. Unveils Transformer Platform to Secure Generative AI and Accelerate Drug DiscoverySeptember 9, 2025 | accessnewswire.comALunai Bioworks Strengthens European Strategy Through RestructuringSeptember 8, 2025 | accessnewswire.comARenovaro BioSciences retains American Defense InternationalSeptember 4, 2025 | msn.comLunai Bioworks Inc. Retains American Defense InternationalSeptember 4, 2025 | accessnewswire.comARenovaro BioSciences to change corporate name to ‘Lunai Bioworks’August 28, 2025 | msn.comRenovaro Inc. Announces Corporate Name Change to Lunai Bioworks, Inc., Reflecting Strategic Focus on AI-Driven Biodefense, Drug Discovery and Advanced DiagnosticsAugust 27, 2025 | accessnewswire.comARenovaro Inc. (NASDAQ: RENB) Mentioned in RealClearDefense Article on AI and Biodefense RisksAugust 8, 2025 | accessnewswire.comARenovaro Biosciences Granted Nasdaq Compliance ExtensionAugust 6, 2025 | tipranks.comAI Just Got a Green Light from the White House--Here's What That Means for Healthcare StocksJuly 30, 2025 | tmcnet.comRenovaro Secures Key AI Patents, Strengthening Market Position in $20B Biomedical AI SectorJuly 28, 2025 | accessnewswire.comARenovaro Biosciences: Peer-Reviewed Study Validates Renovaro's Genetically Engineered Dendritic Cell Therapy with Potent Anti-Tumor EfficacyJuly 17, 2025 | finanznachrichten.dePeer-Reviewed Study Validates Renovaro's Genetically Engineered Dendritic Cell Therapy with Potent Anti-Tumor EfficacyJuly 17, 2025 | accessnewswire.comARenovaro Biosciences Receives Nasdaq Compliance NoticeJuly 14, 2025 | tipranks.comRenovaro Strengthens Balance Sheet Through Debt ... - MorningstarJuly 11, 2025 | morningstar.comMRenovaro Strengthens Balance Sheet Through Debt Conversion and Advances AI-Driven InitiativesJuly 9, 2025 | accessnewswire.comARenovaro Biosciences Restructures Debt with Exchange AgreementJuly 9, 2025 | tipranks.comRenovaro Launches AI-Based Neurotoxin Countermeasure Initiative Addressing Emerging National Security Needs - NasdaqJuly 2, 2025 | nasdaq.comRenovaro Biosciences: Renovaro Launches AI-Based Neurotoxin Countermeasure Initiative Addressing Emerging National Security Needs - FinanzNachrichten.deJuly 2, 2025 | finanznachrichten.deMedia Sentiment Over TimeINBP, MURA, DYAI, and RENB Company DescriptionsDyadic International NASDAQ:DYAI$0.99 +0.03 (+2.62%) Closing price 04:00 PM EasternExtended Trading$0.99 +0.00 (+0.12%) As of 04:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health. The company offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial to demonstrate the safety in humans of a protein produced using the C1 platform. It has also developed the Dapibus thermophilic, a filamentous fungal-based microbial protein production platform to enable the development and large-scale manufacture of cost-effective proteins, metabolites, and other biologic products for use in non-pharmaceutical applications, including food, nutrition, and wellness. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; license agreement with South Africa's Rubic One Health; Joint Development Agreement with a Global Food Ingredient Company; and sub-license agreement with Abic Biological Laboratories Ltd., Alphazyme, LLC, and Abic Biological Laboratories Ltd. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.Integrated BioPharma OTCMKTS:INBP$0.29 0.00 (-1.38%) As of 11:53 AM EasternIntegrated BioPharma, Inc., together with its subsidiaries, manufactures, distributes, markets, and sells vitamins, nutritional supplements, and herbal products primarily in the United States and Luxembourg. It operates through Contract Manufacturing and Other Nutraceutical Businesses segments. The Contract Manufacturing segment manufactures vitamins and nutritional supplements for sale to distributors, multilevel marketers, and specialized health-care providers. The Other Nutraceutical Businesses segment distributes healthful nutritional products for sale through mass market, grocery, drug, and vitamin retailers under the Peaceful Sleep and Wheatgrass brands, as well as other branded proprietary nutraceutical products. This segment also sells private label vitamin and nutritional supplement products through the Internet; provides warehousing and fulfilment services; and distributes fine natural botanicals, including multi minerals, as well as raw materials. The company was formerly known as Integrated Health Technologies, Inc. Integrated BioPharma, Inc. was incorporated in 1980 and is based in Hillside, New Jersey.Mural Oncology NASDAQ:MURA$2.07 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$2.08 +0.01 (+0.24%) As of 07:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab. It also develops nemvaleukin to treat cutaneous melanoma and advanced solid tumors. The company is also developing engineered interleukin-18 and tumor-targeted interleukin-12 programs. Mural Oncology plc was incorporated in 2017 and is based in Dublin, Ireland.Renovaro NASDAQ:RENB$0.18 -0.01 (-4.04%) Closing price 04:00 PM EasternExtended Trading$0.18 0.00 (-0.55%) As of 07:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Renovaro Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer in the United States. The company's product pipeline includes RENB-HV-01 for autologous HIV curative treatment; RENB-HV-12, a therapeutic HIV vaccine; and RENB-HB-01, a gene therapy curative treatment for HBV. It also develops RENB-DC-11, an allogeneic dendritic cell therapeutic vaccine for pancreatic cancer; RENB-DC-12-XX, an allogeneic dendritic cell therapeutic vaccine for other solid tumors; and RENB-HV-21 for treating HIV with allogeneic natural killer (NK) and gamma delta T-cells. It has strategic partnerships with the University of California, Fred Hutchinson Cancer Research Center, and Caring Cross. The company was formerly known as Renovaro Biosciences Inc. and changed its name to Renovaro Inc. in February 2024. Renovaro Inc. is headquartered in Los Angeles, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Resideo Technologies: Institutional Activity Signals 30% Upside Lululemon’s Sell-Off Looks Overdone: A Contrarian Case Palantir’s Commercial Growth Story Is Just Getting Started How Bath & Body Works Is a Perfect Example of a Value Stock The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Uranium Energy Stock Has Momentum—and More Upside Ahead Why Opendoor Stock Is Soaring—and May Just Be Starting Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
